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Abstract: The mechanisms of protection against respiratory syncytial virus (RSV) are poorly
understood. Virus-like nanoparticles expressing RSV glycoproteins (eg, a combination of fusion
and glycoprotein virus-like nanoparticles [FG VLPs]) have been suggested to be a promising
RSV vaccine candidate. To understand the roles of alveolar macrophages (AMs) in inducing
long-term protection, mice that were 12 months earlier vaccinated with formalin-inactivated
RSV (FI-RSV) or FG VLPs were treated with clodronate liposome prior to RSV infection.
FI-RSV immune mice with clodronate liposome treatment showed increases in eosinophils,
plasmacytoid dendritic cells, interleukin (IL)-4+ T-cell infiltration, proinflammatory cytokines,
chemokines, and, in particular, mucus production upon RSV infection. In contrast to FI-RSV
immune mice with severe pulmonary histopathology, FG VLP immune mice showed no overt
sign of histopathology and significantly lower levels of eosinophils, T-cell infiltration, and
inflammatory cytokines, but higher levels of interferon-γ, which are correlated with protection against RSV disease. FG VLP immune mice with depletion of AMs showed increases in
inflammatory cytokines and chemokines, as well as eosinophils. The results in this study suggest that FG nanoparticle vaccination induces long-term protection against RSV and that AMs
play a role in the RSV protection by modulating eosinophilia, mucus production, inflammatory
cytokines, and T-cell infiltration.
Keywords: alveolar macrophage, nanoparticle vaccine, VLP, FI-RSV, RSV disease
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Respiratory syncytial virus (RSV) is a leading cause of a pulmonary disease in children.
In the 1960s, formalin-inactivated RSV (FI-RSV) vaccine was tested in clinical trials,
but it caused severe vaccine-enhanced respiratory diseases leading to high hospitalizations and deaths of two children during the RSV epidemic winter season.1 The cause of
the vaccine-enhanced disease was not fully understood, but the symptoms were known
to be caused by T helper (Th)2-biased immune responses and eosinophil infiltration
in lungs after RSV infection. Since the tragic failure of FI-RSV vaccine trials, there
is no licensed RSV vaccine.1–3
RSV fusion (F) and attachment glycoproteins (G) are major antigenic surface proteins and contain neutralizing antibody and T-cell epitopes. Virus-like nanoparticles
(VLPs) are genetically engineered particles expressing immunogenic proteins.4 VLPs
mimic the structure of a virus but lack viral genomes. Newcastle disease virus-based or
recombinant baculovirus-expressed VLPs containing RSV F and/or G glycoproteins, or
mixed RSV F and G VLPs (FG VLPs), were shown to elicit antigen-specific antibody
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production and provide protection against RSV infection in
mouse models.5–9 Compared to FI-RSV, immunization with
RSV VLP vaccines induced a higher IgG2a/IgG1 antibody
ratio, which refers to Th1 immune responses.5,6 Nanoparticles
of FG VLPs were shown to be in a range of 60–120 nm-size
particles and produced in insect cells using the recombinant
baculovirus expression system.5
Alveolar macrophages (AMs) are the first defense line of
innate immune cells in the respiratory tract. AMs are a major
resident cell in alveoli and interstitial spaces of the lung.10
AMs can eliminate the foreign antigens by phagocytosis
and microbicidal enzymes, and also regulate inflammatory
responses by secreting proinflammatory cytokines such as
interferon (IFN)-γ and tumor necrosis factor (TNF)-α.11,12
AMs are known to be required to induce protective immune
responses against bacteria, fungi, and viruses.13 Dendritic cells
(DCs) together with AMs are major antigen-presenting cells
in the lungs. Respiratory DCs play a crucial role in inducing adaptive immune responses.14 Monocyte-derived DCs
are phenotypically immature and poor activators of naïve
T-cells, although they are able to transport antigens from the
lungs to the draining lymph node.15 In addition, AMs have
anti-inflammatory activity to inhibit antigen presentation of
DCs.16 However, the roles of AMs in the RSV protection and
disease after vaccination largely remain unknown.
Here, we investigated the potential effects of AMs on longterm protection, Th1 and Th2 cytokines, modulating innate and
adaptive cellular phenotypes, and vaccination-induced inflammatory disease in mice that were a year earlier immunized with
FG VLPs or FI-RSV. Clodronate liposomes (CLs) have been
used to deplete tissue macrophages. CL is an apoptosis-inducing
agent and uses phagocytic properties of macrophages that
uptake CL.17,18 In contrast to FI-RSV, FG VLPs conferred longterm protection against RSV without causing vaccine-enhanced
RSV disease by appropriately modulating granulocytes, cytokines, and T-cells toward Th1-type immune responses. Depletion
of AMs resulted in differential effects on DCs, eosinophils,
inflammatory cytokines, and T-cells as well as mucus production in the lungs of mice with different immunization history
upon RSV infection, suggesting important roles of AMs in
modulating innate and adaptive immunity.

Materials and methods
Preparation of F and G VLPs and FI-RSV
The VLPs containing RSV F or G were produced using
Spodoptera frugiperda SF9 insect cells (ATCC CRL-1711)
as previously described.5 Briefly, SF9 insect cells maintained
in SF900-II serum-free medium were coinfected5 with recombinant baculoviruses expressing influenza matrix core protein
4492
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(M1) and full-length RSV F or RSV G surface proteins. After
2 days of culture, RSV F and G VLPs were purified from
the culture supernatants using ultracentrifugation and found
to have spherical sizes of 60–120 nm and to express RSV
F and G proteins, respectively.5 HEp-2 cells were obtained
from American Type Culture Collection (ATCC) (Manassas,
VA, USA) and maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Thermo Fisher Scientific, Waltham, MA,
USA). RSV A2 strain was used for FI-RSV preparation and
RSV challenge. RSV was grown in HEp-2 cells, harvested,
and inactivated with formalin for 3 days at 37°C. FI-RSV
was collected by ultracentrifugation and its inactivation confirmed by an immune-plaque assay.5 FI-RSV was adsorbed
to aluminum hydroxide adjuvants (alum, 4 mg/mL) and used
for immunization of mice.

Mice and immunization
Balb/c mice were purchased from Harlan (Indianapolis, IN,
USA) and maintained in the Georgia State University (GSU)
(Atlanta, GA, USA) animal facility under the guidelines of
the GSU Institutional Animal Care and Use (IACUC) protocol. Female Balb/c mice aged 3 weeks (n=10 per group) were
primed with FI-RSV (1 μg) or FG VLPs (10 μg of each VLP),
and then boosted with the same dose 4 weeks later.

RSV-specific serum enzyme-linked
immunosorbent assay
To determine RSV-specific serum antibodies at 1 month and
12 months after boost immunization, enzyme-linked immunosorbent assay (ELISA) was performed using an FI-RSV
(400 ng/well) antigen as previously described.5,19

Clodronate treatment and RSV challenge
Specific tissue macrophages can be depleted by choosing an
appropriate administrative route.18,20 AMs can be selectively
depleted in lungs through intranasal administration of the
CL.21 Before RSV infection, naïve, FI-RSV-immunized, and
FG VLP-immunized mice were treated intranasally with
100 μL of phosphate-buffered saline (PBS) or CL to deplete
AMs in the respiratory tract and lung. After 4 hours, RSV A2
strain (2×106 plaque-forming units) was used to challenge
PBS-treated and CL-treated mice.

Preparation of bronchoalveolar lavage
fluid and lung samples after challenge
At day 5 post-RSV challenge, the mice were euthanized
to collect bronchoalveolar lavage fluid (BALF) and lung
samples. BALF samples were obtained by infusing 1 mL
of PBS into the lungs via trachea using an 18-gauge and
International Journal of Nanomedicine 2015:10
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1¼-inch catheter (Exelint International Co., Saint Petersburg,
FL, USA). BALF and bronchoalveolar lavage (BAL) cells
were separated after centrifugation. The collected lungs
were homogenized and centrifuged to get lung extracts and
to produce single cell suspension. The homogenized lung
tissues were digested with 150 U/mL collagenase (Thermo
Fisher Scientific) in RPMI 1640 medium supplemented
with 1 mM MgCl2, 1 mM CaCl2, and 5% fetal calf serum
at 37°C for 90 minutes. The whole lung cell suspensions
were treated on 44%/67% Percoll gradients at 2,800 rpm for
15 minutes, and the immune cell-enriched layer was harvested, washed, and used for further experiments.22

Immune-plaque assay
To determine viral loads in lung extracts from naïve and
immunized mice after RSV challenge infection, an immuneplaque assay was performed as described before.5 Briefly,
the lung extracts day 5 post-challenge were serially diluted
and applied to the confluent HEp-2 cell monolayer. After 2
hours’ incubation, the lung extracts were removed and the
infected HEp-2 cells were cultured for 3 to 5 days until plaque
formation by RSV. Then, the RSV plaques were detected by
anti-RSV F monoclonal antibody (EMD Millipore, Billerica,
MA, USA) and 3,3′-diaminobenzidine substrate.

Flow cytometry
To analyze detailed cell subsets in respiratory tract after
CL treatment and RSV challenge, the BAL and lung cells
were stained with fluorescence-labeled anti-mouse CD45,
CD11b, CD11c, CD3, CD4, CD8, B220, F4/80, and Siglec F
antibodies in the presence of anti-mouse CD16/32 antibodies. The surface marker expressions of the stained cells were
acquired by BD Fortessa (BD Biosciences, San Jose, CA,
USA) and analyzed by FlowJo (Tree Star Inc., Ashland,
OR, USA).

Cytokine ELISA
Cytokine production of the RSV-challenged mice was determined by ELISA. BALF and lung extracts from the RSVchallenged mice were analyzed by mouse interleukin (IL)-5,
IL-6, IL-13, TNF-α, and IFN-γ ELISA Ready-Set-Go® kits
(eBioscience, San Diego, CA, USA) and mouse eotaxin and
macrophage inflammatory protein-1 beta (MIP-1β) duoset®
(R&D Systems Inc., Minneapolis, MN, USA) following the
manufacturer’s protocol.

Cytokine enzyme-linked immunospot
Lung cells were obtained from mice euthanized at day
5 post-challenge as described above. The lung cells
International Journal of Nanomedicine 2015:10
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(5×105 cells/well) were seeded and cultured in anti-mouse IL-4or IFN-γ-coated plates. The cells were treated with RSV F92–106
(ELQLLMQSTPPTNNR) or RSV G183–195 (WAICKRIPNKKPG)
for 3 days to stimulate antigen-specific cytokine-producing cells.
The number of IL-4- or IFN-γ-secreting cell spots was counted
using an ELIspot Bioreader 5000 (BioSys, Miami, FL, USA).

Lung histopathology
For histological analysis, intact lungs from the challenged
mice were harvested at day 5 post-challenge. The lungs were
fixed in 10% neutral formalin and processed with ethanol
and xylene as described previously.23 The lung sections
were stained with hematoxylin and eosin for evaluation of
the lung inflammation and periodic acid–Schiff (PAS) stain
for mucus production. Photographs were acquired under a
microscope (Zeiss Axiovert 100; Carl Zeiss Meditec AG,
Jena, Germany) at a magnification of 20, using an attached
digital camera (Canon 30D; Canon, Japan). For lung histopathology assessment, blinded scoring in bronchiole, vessels,
and interstitial spaces was performed. The scores were in
a range of 0 (no inflammation) to 3 (severe inflammation)
following the criteria of the scoring system.24 PAS-positive
areas were calculated using the Photoshop program.

Statistical analysis

Experimental results are presented as mean ± standard error of
the mean. Data were analyzed using Prism software (GraphPad
Software, Inc., La Jolla, CA, USA). Statistical analysis was
performed by unpaired two-tailed Student’s t-test. Probability values less than 0.05 were considered to be statistically
significant.

Results
FG VLPs confer long-lasting protection
against RSV
It is desirable to induce long-lasting protective antibody
responses after vaccination. The groups of mice were
primed and boost-immunized with FI-RSV or FG VLPs
at a 4-week interval, and RSV-specific antibody responses
were determined. Antibody levels were similar at 1 and
12 months post-immunization, suggesting that long-lasting
RSV-specific antibodies were induced by FI-RSV or FG
VLP immunization (Figure 1A). To determine the protective
efficacy of FG VLP vaccination, naïve and immunized mice
were challenged with live RSV. Viral titers were observed at
higher levels in the lungs of unimmunized mice after RSV
infection compared to FI-RSV- or FG VLP-immunized mice
that lowered lung viral loads by over 1,000-fold (Figure 1B).
Therefore, immunization of mice with FI-RSV or FG VLP
submit your manuscript | www.dovepress.com
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Figure 1 Immunization with FG VLP induces long-lasting humoral immunity and protection against RSV.
Notes: Balb/c mice (n=10) were intramuscularly immunized with FI-RSV or FG VLP at week 0 (at the age of 3 weeks old) and boosted 4 weeks later. (A) RSV-specific
IgG antibodies in immune sera from the FI-RSV and FG VLP group, respectively. RSV-specific antibodies were determined by enzyme-linked immunosorbent assay at
1 or 12 months after immunization. Total IgG, IgG1, and IgG2a antibodies specific for RSV were determined from mice immunized with FI-RSV or FG VLP. The results
are representative out of two independent experiments. (B) Lung samples from mice (n=5) treated intranasally with PBS (control) or CL were harvested day 5 post-RSV
challenge. Lung viral loads were determined by an immune-plaque assay. Statistical significance was determined using an unpaired two-tailed Student’s t-test. Error bars
indicate means ± standard error of the mean of concentration or ratios from individual animals. *P,0.01.
Abbreviations: CL, clodronate liposome; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles; FG VLP + RSV, FG VLP immune mice with RSV infection;
FI-RSV, formalin-inactivated RSV; FI-RSV + RSV, FI-RSV immune mice with RSV infection; Naïve + RSV, unimmunized naïve mice with RSV infection; OD, optical density;
PBS, phosphate-buffered saline; pfu, plaque-forming units; RSV, respiratory syncytial virus.

induced high efficacy of protection by effectively clearing
lung viral loads even at 12 months after vaccination.
AMs were found to be dominantly present in the airways
from naïve mice (Figure S1), which is consistent with a
previous study.25 To determine the possible roles of AMs
in protective immunity and RSV disease in mice with vaccination, CL was intranasally given to mice that were previously immunized with FI-RSV or FG VLP 1 year before.
Depletion of AMs (CD11c+CD11b–F4/80+) was confirmed
by flow cytometry analysis (Figure S1A).21,26,27 AMs in the
airways were significantly reduced in naïve and FG VLP
immune mice, and, particularly, FI-RSV immune mice
showed the lowest level of AMs after RSV infection even
without CL treatment (Figure S1B). CL treatment resulted in

4494
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further decreases in the percentages of AMs in the airways
(Figure S1B).
Lung viral loads from the groups of mice were determined in the presence or absence of CL administration 5 days
post-challenge. CL treatment of naïve mice resulted in a
further decrease (approximately 30%) in viral loads from the
lungs compared to PBS-treated mice (Figure 1B). A pattern of
reducing viral loads was observed in CL-treated FI-RSV mice,
but there was no significance between PBS- and CL-treated
FI-RSV mice. FG VLP mice with CL treatment showed a
slightly further reduction in viral loads from the lungs compared to nontreated mice. Taken together, these data indicate
that vaccination with FI-RSV or FG VLPs induces long-lasting
humoral immunity primarily responsible for controlling lung
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Differential mobilization of pulmonary
DCs after clodronate treatment
To further understand the effect of depleting AM population
in modulating pulmonary DCs, we analyzed distinct subsets
of DCs including CD11b+ DCs (CD11b+CD11c+F4/80–
CD45+) and plasmacytoid DCs (pDCs) (B220+CD11c+F4/80–
CD45+).28,29 After RSV infection, pDCs in the airways were
observed at similar levels in the naïve and FG VLP groups
regardless of CL treatment, but CL-treated FI-RSV mice
showed substantially increased numbers of pDCs than those
in PBS-treated FI-RSV mice (Figure 2A). The pDC numbers
in the lungs were lower in the FI-RSV group compared to
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the naïve-infected mice (Figure 2B). Similar numbers of
pDCs were observed in the lungs between the groups of
mice with and without CL administration. CD11b+ DCs were
observed at similar levels in the BAL or lungs of the naïve,
FI-RSV, and FG VLP groups regardless of CL treatment
(Figure 2C and D). These data suggest that AMs may have
an inverse correlation with pDCs in the airways of FI-RSV
immune mice, but not in naïve and FG VLP immune mice.

Airway AM depletion increases eosinophil
recruitment and chemokine production
To understand whether CL treatment influenced eosinophilia in
the lungs during RSV infection, eosinophil infiltration was analyzed by using the surface markers (CD11b+Siglec F+CD11c–).
Approximately 10- to 50-fold higher numbers of eosinophils
were detected in the BAL and lungs of FI-RSV immune mice
than those in naïve or FG VLP immune mice day 5 post-RSV
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viral loads. Levels of AMs were significantly reduced in
naïve and FG VLP mice, and, in particular, the FI-RSV group
showed the lowest AMs upon RSV infection. CL treatment
resulted in further depleting AMs in the airways.
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Figure 2 Effects of CL treatment on DC populations in the airways and lungs upon RSV challenge.
Notes: The BAL fluid and lung tissues from individual mice (n=5) were collected 5 days after RSV challenge. Distinct DC subsets were analyzed by flow cytometry using the
surface markers CD45, CD11c, CD11b, B220, and F4/80. (A and B) Plasmacytoid DCs (B220+CD11c+F4/80–CD45+) and (C and D) CD11b+ DCs (CD11b+CD11c+F4/80–
CD45+) were analyzed in the airways and lungs. PBS panel: mock (PBS)-treated groups. CL panel: CL-treated groups. The results are representative out of two independent
experiments. Statistical significance was determined (n=5) using an unpaired two-tailed Student’s t-test. Error bars indicate means ± standard error of the mean of
concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: BAL, bronchoalveolar lavage; CL, clodronate liposome; DC, dendritic cell; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-RSV,
formalin-inactivated RSV; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.
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challenge (Figure 3A and B). Interestingly, CL treatment
resulted in increases in numbers of eosinophils in the BAL and
lungs of FI-RSV immune mice (Figure 3A and B). Eosinophils
were increased to a moderate level in the BAL of naïve and
FG VLP mice with CL treatment (Figure 3A). Importantly, we
found that CL treatment resulted in significant increases in the
levels of eotaxin and MIP-1β from the lungs and BAL samples
of all groups of mice except the BAL eotaxin from the FG
group (Figure 3C and D). These results suggest that AMs may
contribute to modulating the production of chemoattractants
and eosinophil recruitment in FI-RSV immune mice, although
chemokine levels alone do not explain the enormous infiltration
of eosinophils into the lungs of FI-RSV immune mice.

FG VLP immunization induces IFN-γ but
not proinflammatory cytokines after RSV
infection
It has been demonstrated that imbalanced cytokines resulted
in vaccine-enhanced RSV disease.30 Proinflammatory and
antiviral cytokines were analyzed in the BALF and lung

A

extracts from each group of mice upon RSV infection. Th1
cytokine IFN-γ in BAL and lung samples was detected at the
lowest levels in the FI-RSV group (Figure 4A). In contrast,
significantly higher levels of IFN-γ in BALF (Figure 4A)
and in lungs (Figure 4A) were observed in FG VLP immune
mice compared to those in the FI-RSV group. Naïve mice
also exhibited moderate levels of IFN-γ in BAL and lung
samples (Figure 4A). CL treatment resulted in an increase in
IFN-γ production from the lungs of FG VLP immune mice
and in BAL IFN-γ levels from RSV-infected naïve mice
(Figure 4A). TNF-α proinflammatory cytokine levels were
observed at relatively higher levels in naïve RSV-infection
mice (Figure 4B). The levels of TNF-α were found to be
increased in both BAL and lung samples from all groups of
mice with CL treatment (Figure 4B).
Noticeably, high levels of Th2 cytokines such as IL-5,
IL-6, and IL-13 were observed in the lung extracts from
FI-RSV immune mice but not from FG VLP immune mice
(Figure 4C–E). High levels of Th2 cytokines (IL-5, IL-6,
IL-13) were detected in BAL samples from naïve-infected
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Figure 3 CL-mediated depletion of alveolar macrophages increases eosinophil recruitments and chemokine expression.
Notes: (A and B) Flow cytometry analysis of immune cells from BAL and lungs was used to investigate the pattern of eosinophil infiltration. (A) The surface markers such as
CD11c, CD11b, and Siglec F were used to characterize eosinophil infiltration. For flow cytometric gating of eosinophils (the circled areas), CD11b+ population was first gated
and further analyzed into Siglec F and CD11c in BAL and lung samples. PBS panel: mock (PBS)-treated groups. CL panel: CL-treated groups. (B) The numbers of eosinophils
in BAL and lung samples. (C and D) BAL and lung lysates were also used to determine chemokine levels 5 days post-RSV challenge. (C) Eotaxin in BAL and lung extract. (D)
MIP-1β in BAL and lung extract. The eosinophil chemoattractants (eotaxin, MIP-1β) were determined in the airways and lungs. The results are representative out of two
independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test. Error bars indicate means ± standard error of the mean of
concentration or ratios from individual animals (n=5). *P,0.05; **P,0.01; ***P,0.001.
Abbreviations: BAL, bronchoalveolar lavage; CL, clodronate liposome; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-RSV, formalininactivated RSV; MIP-1β, macrophage inflammatory protein-1 beta; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.

mice (Figure 4C–E). Also, FI-RSV immune mice treated with
CL showed significantly increased levels of Th2 cytokines
including IL-5, IL-6, and IL-13 in the airways of BAL fluids
(Figure 4C–E). In contrast, FG VLP immune mice did not
show increases in IL-5 and IL-13 cytokines regardless of CL
treatment (Figure 4C and E). Meanwhile, IL-6 production in
IFN-γ in BAL
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suggest that airway AMs play a differential role in modulating
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Figure 4 CL-mediated depletion of alveolar macrophages differentially modulates Th1 and Th2 cytokines in the lungs.
Notes: Inflammatory cytokines were determined in BAL fluid and lung lysates day 5 post-RSV challenge (n=5). (A) IFN-γ. (B) TNF-α. (C) IL-5. (D) IL-6. (E) IL-13. Th1-type cytokines
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inflammatory and antiviral cytokines in the BAL airways
and lungs upon RSV infection. More importantly, the type of
vaccine appears to be a primary determinant of cytokine profiles induced in the airways and lungs upon RSV infection.

CL treatment of FI-RSV immune mice
increases T-cell recruitment but reduces
IFN-γ T-cell responses
A trend of inducing higher numbers of CD8+ and CD4+
T-cells was observed in the BAL from the FI-RSV group with
CL treatment (Figure 5A and B). High levels of BAL and lung
CD8+ T-cells were shown in the FG group (Figure 5A and C).
As a result of CL treatment, the FI-RSV group displayed
a significant increase in numbers of lung CD8+ and CD4+
T-cells (Figure 5C and D).
To further characterize whether CL treatment altered RSV
antigen-specific T-cell responses, the cells from the lungs 5 days
after RSV challenge were in vitro stimulated with the synthetic

A

Total CD8+ T-cells in BAL

F92–106 (ELQLLMQSTPPTNNR) and G183–195 (WAICKRIPNKKPG) peptides which are RSV-specific CD8+ and CD4+ T-cells,
respectively.31 The cytokine-positive spots were counted using
an enzyme-linked immunospot reader. The FI-RSV immune
group showed the highest levels of IL-4-positive spots with
stimulation of F or G peptides, whereas IL-4 spot numbers
were similarly low in the lungs of naïve and FG VLP immune
mice (Figure 6A). There was no significant change in the
numbers of IL-4-positive spots with CL treatment. In addition, higher numbers of IFN-γ-positive spots after stimulation
with G peptide were detected in the FI-RSV group compared
to those in the naïve and FG VLP groups (Figure 6B). Also,
F peptide-stimulated IFN-γ spots were relatively high in the
lungs from FI-RSV immune mice, but there were no statistical
significances compared to other groups. Noticeably, CL-treated
FI-RSV mice showed dramatically reduced numbers of IFN-γpositive spots in both F and G peptide-stimulated lung cells
(Figure 6B). These data suggest that AMs in FI-RSV immune
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Figure 5 CL treatment differentially regulates T-cell recruitment in the lungs.
Notes: The cells were harvested from the airways and lungs of individual mice 5 days post-challenge and cellularity of T-cells was analyzed by flow cytometry. (A) BAL CD8+
T-cells. (B) BAL CD4+ T-cells. (C) Lung CD8+ T-cells. (D) Lung CD4+ T-cells. Total numbers of CD3+CD8+ T-cells and CD3+CD4+ T-cells were determined in BAL and lungs
(n=5). PBS panel: mock (PBS)-treated groups. CL panel: CL-treated groups. Statistical significance was determined using an unpaired two-tailed Student’s t-test. Error bars
indicate means ± standard error of the mean of concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: BAL, bronchoalveolar lavage; CL, clodronate liposome; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles, FI-RSV, formalininactivated respiratory syncytial virus; PBS, phosphate-buffered saline.

International Journal of Nanomedicine 2015:10

submit your manuscript | www.dovepress.com

Dovepress

4499

Dovepress

FI-RSV
FG VLP

F peptide

B

Naïve

G peptide

G peptide

A

F peptide

Lee et al

Naïve
FI-RSV
FG VLP
0

50

100

150

200

Naïve
FI-RSV

**

FG VLP
Naïve
FI-RSV

*

FG VLP

250

0

IL-4+ spots/1×105 cells

40

20

60

80

100

IFN-γ spots/1×10 cells
+

PBS

5

CL

Figure 6 FI-RSV immune mice induce extreme levels of F and G peptide-stimulated pulmonary IL-4+ CD4 T-cells.
Notes: Immune cells were collected from the lungs 5 days post-challenge with RSV (n=5). (A) IL-4+ and (B) IFN-γ+ spots were determined after cells were stimulated with
RSV F92–106 (ELQLLMQSTPPTNNR) or RSV G183–195 (WAICKRIPNKKPG) for 3 days. PBS panel: mock (PBS)-treated groups. CL panel: CL-treated groups. The results are
representative out of two independent experiments. Statistical significance was determined using an unpaired two-tailed Student’s t-test. Error bars indicate means ± standard
error of the mean of concentration or ratios from individual animals. *P,0.05; **P,0.01.
Abbreviations: CL, clodronate liposome; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-RSV, formalin-inactivated RSV; IFN-γ, interferongamma; IL, interleukin; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.

mice may modulate inflammatory adaptive responses as well
as antigen-specific T-cell responses in lungs.

as evidenced by significantly less cellular infiltrates (FG VLP +

FI-RSV but not FG VLP causes severe
pulmonary mucus production and
inflammation

inflammation were observed in the airways, blood vessels,

Pulmonary histopathology was analyzed to assess the safety
concerns of FG VLP vaccines and the possible effects of CL
treatment in vaccinated mice upon RSV infection 1 year later.
The FI-RSV group showed severe leukocyte infiltrates compared to the FG VLP group (Figure 7A). Also, naïve aged mice,
upon RSV infection, showed severe inflammatory histology
around the blood vessels and interstitial spaces (naïve + RSV
with PBS, Figure 7A and B). Importantly, FG VLP immune
mice did not display such obvious pulmonary histopathology
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RSV with PBS, Figure 7A). The highest levels of histological
and interstitial spaces from FI-RSV immune mice compared
to those from the naïve and FG VLP groups (Figure 7B). CL
treatment did not induce lung inflammation in naïve uninfected
mice (naïve, Figure 7). CL treatment of FI-RSV immune mice
did not show apparent changes in histopathology probably due
to the full-blown severe histopathology, but showed a trend
of further increasing inflammation scores to the maximum
(FI-RSV + RSV, Figure 7B). Naïve mice with CL treatment
showed a trend of lowering infiltrates and lung inflammation
scores (naïve + RSV with CL, Figure 7A and B). In contrast,
FG VLP immune mice with CL treatment showed a moderate
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Figure 7 CL-mediated depletion of alveolar macrophages differentially modulates histopathology and mucus production.
Notes: The lung tissues from mice were collected 5 days after RSV challenge. The lung tissues were fixed with 10% neutral buffered formalin solution and embedded in
paraffin. (A) Histology photographs of hematoxylin and eosin staining. (B) Histopathological scores. (C) Histology photographs of PAS staining. (D) Percentages of PASpositive area. Histopathological scores were determined in the airways, blood vessels, and interstitial spaces. PBS panel: mock (PBS)-treated groups. CL panel: CL-treated
groups. Representative histology photographs from each group were taken and scale bars indicate 100 μm. The reproducible data were obtained from two independent
experiments (n=3–5). Statistical significance was determined using an unpaired two-tailed Student’s t-test. Error bars indicate means ± standard error of the mean of
concentration or ratios from individual animals (n=5). *P,0.05; **P,0.01.
Abbreviations: CL, clodronate liposome; FG VLP, a combination of fusion and glycoprotein virus-like nanoparticles; FI-RSV, formalin-inactivated RSV; PAS, periodic
acid–Schiff; PBS, phosphate-buffered saline; RSV, respiratory syncytial virus.
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trend of increasing infiltrates and lung inflammation scores
(FG VLP + RSV with CL, Figure 7A and B).
Significant mucus production was observed in PASstained lung sections from FI-RSV immune mice and a low
level of PAS-positive mucus was also detected in lung samples from naïve mice upon RSV infection (Figure 7C and D).
In contrast, PAS-positive mucus production was not observed
in FG VLP mice after RSV infection. More importantly, CL
treatment of FI-RSV-immunized mice resulted in a significant
increase in PAS positivity, suggesting more pulmonary mucus
production (Figure 7C and D). CL treatment of naïve mice
resulted in lowering mucus production upon RSV infection
(naïve + RSV with CL, Figure 7C and D). These data suggest that FG VLP immunization does not cause pulmonary
inflammation and infiltrates even 1 year after vaccination and
that AMs play a role in regulating pulmonary inflammation
and mucus production during RSV infection.

Discussion
Long-term protection against RSV by vaccination is highly
desirable, since the elderly are also a target population for
RSV disease in addition to young children. However, a
safety concern of vaccine-enhanced RSV disease has been a
challenge in developing effective and safe RSV vaccines. In
this study, at 12 months after vaccination of mice, we found
that FI-RSV and FG VLP immunization induced long-lasting
RSV-specific antibody responses and lowered lung viral loads
close to a detection limit upon RSV infection. It supports that
lung viral clearance is largely dependent on RSV antibodies
induced by vaccination. The effective control of lung viral
loads in FI-RSV immune mice is consistent with that of previous studies.6,7,9,19,23 Herein, we addressed long-term vaccine
safety concerns of FG VLP vaccines and investigated innate
and adaptive cellular immune components that are likely
responsible for RSV protection or pulmonary inflammation
upon RSV infection.
AMs were found to be a major phenotypic cell present in
the airways in uninfected naïve mice as well as RSV-infected
naïve and FG VLP mice. However, AMs were significantly
reduced in FI-RSV immune mice after RSV infection. In
addition, the cellularity of AMs was differentially regulated
between in the airways and in lung tissues. Interestingly, AM
cellularity in the lungs (data not shown) was substantially
reduced in both naïve and FI-RSV immune mice that showed
severe pulmonary inflammation, indicating that AMs might
play an important role in RSV pathogenesis. Therefore, the
possible roles of AMs in the RSV protection or disease were
investigated in vaccinated mice by applying intranasal CL
administration. CL has been shown to deplete macrophage
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phenotypic cells.18 Percentages of AMs in the airways were
substantially reduced in naïve, FI-RSV, and FG VLP mice as
a result of CL treatment prior to RSV infection (Figure S1).
Based on this observation, we could determine the possible
roles of airway AMs in modulating DCs, eosinophils, chemokines, Th1 and Th2 cytokines, RSV-specific CD4+ and CD8+
T-cells, and histopathology among different RSV-vaccinated
groups. Although there were differential effects of CL treatment depleting AMs, the type of RSV vaccine was found to
be the most critical factor in determining the outcome of host
immune responses and protection.
The effects of CL treatment prior to RSV infection were
found to be differential among naïve, FI-RSV, and FG VLP
immune mice. CL treatment caused two- to threefold increases
in eosinophils in the airways and lungs from FI-RSV immune
mice that showed the highest levels of eosinophil infiltration.
There were fourfold increases in the numbers of B220+ pDCs
in the airways of FI-RSV immune mice with CL treatment but
not in naïve or FG VLP immune mice. Meanwhile, limited
increases in eosinophils were observed in naïve or FG VLP
mice as a result of CL treatment. Also, cellularity in CD4+ and
CD8+ T-cells was significantly increased in the lungs of FI-RSV
immune mice as a result of CL treatment but not in other groups
of mice. This is in line with a previous finding that antigen
presentation is required for T-cell migration into the lungs.22 In
contrast, RSV-specific CD4+ and CD8+ T-cells producing IFN-γ
were substantially reduced in the lungs of FI-RSV immune
mice after CL treatment. Thus, it is also possible that reduced
IFN-γ-producing cells and increases in eosinophils, pDCs,
and CD4+ and CD8+ T-cell cellularity in the lungs might have
contributed to further causing the mucus production and severe
lung histopathology in FI-RSV immune mice. Eosinophils and
IL-4-producing lung T-cells are likely the most significant cellular factors contributing to severe histopathology in FI-RSV
immune mice in addition to the induction of other Th2-type
cytokines regardless of CL pretreatment.
Types of cytokines are known to be involved in vaccineenhanced RSV disease.2,32 The highest levels of IL-5 and
IL-13 were induced in the lungs from FI-RSV but not in FG
VLP immune mice upon RSV infection, which have a correlation with severe pulmonary histopathology. In addition,
extremely high levels of IL-4-producing lung cells in FI-RSV
but not in FG VLP immune mice were detected independent
of CL treatment after RSV challenge. High levels of IL-5 and
IL-6 cytokines in the airways and lungs were detected in live
RSV previously infected mice with CL treatment upon RSV
reinfection, which seems to be associated with enhanced pulmonary inflammation (data not shown). In support of this, the
FI-RSV group showed increases in the levels of Th2 cytokines
International Journal of Nanomedicine 2015:10
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including IL-5, IL-6, and IL-13 as well as eosinophils in the
airways, supporting the evidence that these Th2 cytokines were
contributing to further mucus secretion in FI-RSV but not in FG
VLP immune mice. The cause of FI-RSV vaccine-enhanced
disease is not fully understood yet, but is assumed to be caused
by multiple parameters including FI-RSV vaccine-induced
Th2-biased immune responses (IL-4, IL-5, IL-13), neutrophils,
and eosinophil infiltration in lungs after RSV infection.33,34
The general features of FI-RSV vaccine-enhanced disease as
represented by pulmonary histopathology in humans could be
recapitulated in mice. However, detailed pathological features
of RSV disease appear to be different in mice and humans.
Naïve mice are less permissive to RSV infection and disease
and require high RSV challenge doses for significant lung viral
loads.35 Severe histopathology and eosinophilia in FI-RSV
immune mice despite lung viral clearance were obvious in mice,
but it is not known whether these same pathological parameters
happen in humans. Regarding these aspects, it is important to
note that, in a murine model, eosinophils and lung viral loads
were not required for FI-RSV vaccine-enhanced disease.2,36,37
Meanwhile, it was noted that, as a result of CL treatment, levels
of TNF-α were increased in the lungs from all RSV-infected
mice. Also, BAL IFN-γ and lung IFN-γ levels were increased in
naïve, FI-RSV, and FG VLP mice as a result of CL treatment,
which might contribute to moderately decreasing lung viral
loads. In line with this, IFN-γ receptor signaling was found to
be critical in controlling dengue virus replication.38
Infection of unimmunized naïve mice with RSV usually
does not induce severe lung histopathology since mice are not
highly permissive to RSV.6,8,23 In this study, we observed a
substantial degree of lung histopathology in naïve mice after
RSV infection probably due to the nature of 1-year-old aged
mice and high lung viral loads. FI-RSV and FG VLP immune
mice as well as live RSV previously infected mice (data not
shown) were found to be highly effective in controlling lung
viral loads by lowering 500- to 1,000-fold. Levels of Th2
cytokines were not high, but there were some cell infiltrates
such as pDCs, CD11b+ DCs, eosinophils, and CD4+ and
CD8+ T-cells and inflammatory cytokines including IL-6,
TNF-α, and IFN-γ in the lungs of RSV-infected naïve mice
compared to those in uninfected naïve mice. Thus, high lung
viral loads, and cellular infiltrates and inflammatory cytokines,
may contribute to pulmonary RSV disease in naïve mice upon
RSV infections at older ages. CL treatment of naïve mice
significantly reduced airway AMs, which resulted in moderate
increases in eosinophils, MIP-1β chemokine, BAL IFN-γ, and
TNF-α and lowering Th2 cytokines. These changes by CL
treatment likely contribute to lung viral control and lessening
pulmonary inflammation. In contrast, a moderate increase
International Journal of Nanomedicine 2015:10
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in histopathology and/or mucus production was observed in
FI-RSV and FG VLP mice with CL treatment. These observations indicate that the effects of CL treatment or possible
roles of AMs can be different depending on the preexisting
immune statuses of mice prior to RSV infection.

Conclusion
FG VLP immunization of mice can induce long-lasting
immunity to RSV infection without causing an overt sign of
pulmonary inflammation. After RSV infection, AMs were
substantially reduced in the airways of FI-RSV immune mice.
In contrast, a high level of AMs was maintained in the lungs
from FG VLP immune mice similar to that from naïve mice
after RSV infection. CL treatment of FG VLP immune mice
partially depleted AMs and resulted in an increase in TNF-α,
IFN-γ, IL-6, and chemokines, which might be associated with
moderate histopathology. In contrast to FG VLP, FI-RSV vaccination induced high levels of eosinophils, IL-4-producing
cells, Th2 cytokines (IL-5 and IL-13), and mucus production
and low levels of IFN-γ, all of which contribute to pulmonary
RSV disease. FI-RSV immune mice with CL showed further
increases in BAL B220+ pDCs, lung eosinophils and chemokines, BAL Th2 cytokines (IL-5, IL-6, IL-13) and TNF-α, and
lung CD4+ and CD8+ T-cells and decreases in RSV F- and
G-specific IFN-γ-secreting cell spots, revealing possible host
immune parameters responsible for FI-RSV vaccine-enhanced
RSV disease. The results in this study provide evidence that
FG VLP immunization confers protection against RSV even
1 year later without vaccine-associated RSV disease and that
AMs play a regulatory role in the RSV disease including
eosinophilia, mucus production, inflammatory cytokines, and
T-cell infiltration.

Acknowledgments
This work was supported by National Institutes of Health/
National Institute of Allergy and Infectious Diseases grants
AI105170, AI093772, and AI119366, to Sang-Moo Kang.

Disclosure
The authors report no conflicts of interest in this work.

References

1. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An
epidemiologic study of altered clinical reactivity to respiratory syncytial
(RS) virus infection in children previously vaccinated with an inactivated
RS virus vaccine. Am J Epidemiol. 1969;89(4):405–421.
2. Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for
respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol. 2003;170(4):2037–2045.
3. Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial
virus (RSV) vaccine-enhanced disease. Immunol Res. 2007;39(1–3):
225–239.
submit your manuscript | www.dovepress.com

Dovepress

4503

Dovepress

Lee et al
4. Zeltins A. Construction and characterization of virus-like particles: a
review. Mol Biotechnol. 2013;53(1):92–107.
5. Quan FS, Kim Y, Lee S, et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis.
2011;204(7):987–995.
6. McGinnes LW, Gravel KA, Finberg RW, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing
the respiratory syncytial virus F and G proteins. J Virol. 2011;85(1):
366–377.
7. Lee S, Quan FS, Kwon Y, et al. Additive protection induced by mixed
virus-like particles presenting respiratory syncytial virus fusion or
attachment glycoproteins. Antiviral Res. 2014;111:129–135.
8. Murawski MR, McGinnes LW, Finberg RW, et al. Newcastle disease
virus-like particles containing respiratory syncytial virus G protein
induced protection in BALB/c mice, with no evidence of immunopathology. J Virol. 2010;84(2):1110–1123.
9. Ko EJ, Kwon YM, Lee JS, et al. Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells. Nanomedicine. 2015;11(1):
99–108.
10. Bowden DH. The alveolar macrophage. Environ Health Perspect. 1984;
55:327–341.
11. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis. 1990;141(2):
471–501.
12. Rubins JB. Alveolar macrophages: wielding the double-edged
sword of inflammation. Am J Respir Crit Care Med. 2003;167(2):
103–104.
13. Schneider C, Nobs SP, Heer AK, et al. Alveolar macrophages are
essential for protection from respiratory failure and associated morbidity following influenza virus infection. PLoS Pathog. 2014;10(4):
e1004053.
14. Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to
respiratory virus infection. Nat Rev Immunol. 2012;12(4):295–305.
15. Kim TS, Braciale TJ. Respiratory dendritic cell subsets differ in their
capacity to support the induction of virus-specific cytotoxic CD8+
T cell responses. PLoS One. 2009;4(1):e4204.
16. Holt PG, Oliver J, Bilyk N, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident
alveolar macrophages. J Exp Med. 1993;177(2):397–407.
17. van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages
induced by liposome-mediated intracellular delivery of clodronate and
propamidine. J Immunol Methods. 1996;193(1):93–99.
18. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1–2):83–93.
19. Lee JS, Kwon YM, Hwang HS, et al. Baculovirus-expressed viruslike particle vaccine in combination with DNA encoding the fusion
protein confers protection against respiratory syncytial virus. Vaccine.
2014;32(44):5866–5874.
20. van Rooijen N, Hendrikx E. Liposomes for specific depletion of
macrophages from organs and tissues. Methods Mol Biol. 2010;605:
189–203.
21. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination
in vivo is associated with an increase in pulmonary immune response
in mice. J Exp Med. 1989;170(2):499–509.

4504

submit your manuscript | www.dovepress.com

Dovepress

22. Lee YT, Suarez-Ramirez JE, Wu T, et al. Environmental and antigen
receptor-derived signals support sustained surveillance of the lungs
by pathogen-specific cytotoxic T lymphocytes. J Virol. 2011;85(9):
4085–4094.
23. Hwang HS, Kwon YM, Lee JS, et al. Co-immunization with viruslike particle and DNA vaccines induces protection against respiratory
syncytial virus infection and bronchiolitis. Antiviral Res. 2014;110:
115–123.
24. Meyerholz DK, Griffin MA, Castilow EM, Varga SM. Comparison
of histochemical methods for murine eosinophil detection in an RSV
vaccine-enhanced inflammation model. Toxicol Pathol. 2009;37(2):
249–255.
25. Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac
Soc. 2005;2(5):403–411.
26. Hall JD, Woolard MD, Gunn BM, et al. Infected-host-cell repertoire
and cellular response in the lung following inhalation of Francisella
tularensis Schu S4, LVS, or U112. Infect Immun. 2008;76(12):
5843–5852.
27. van Rooijen N, Bakker J, Sanders A. Transient suppression of macrophage functions by liposome-encapsulated drugs. Trends Biotechnol.
1997;15(5):178–185.
28. Sung SS, Fu SM, Rose CE Jr, Gaskin F, Ju ST, Beaty SR. A major
lung CD103 (alphaE)-beta7 integrin-positive epithelial dendritic cell
population expressing Langerin and tight junction proteins. J Immunol.
2006;176(4):2161–2172.
29. Beaty SR, Rose CE Jr, Sung SS. Diverse and potent chemokine production by lung CD11b high dendritic cells in homeostasis and in allergic
lung inflammation. J Immunol. 2007;178(3):1882–1895.
30. Bueno SM, González PA, Riedel CA, Carreño LJ, Vásquez AE, Kalergis AM.
Local cytokine response upon respiratory syncytial virus infection.
Immunol Lett. 2011;136(2):122–129.
31. Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant
epitope that elicits both Th1 and Th2 CD4+ T cell responses. J Immunol.
2000;165(11):6487–6495.
32. Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an
IL-4-independent mechanism. J Virol. 1999;73(10):8485–8495.
33. Bueno SM, González PA, Pacheco R, et al. Host immunity during RSV
pathogenesis. Int Immunopharmacol. 2008;8(10):1320–1329.
34. Bataki EL, Evans GS, Everard ML. Respiratory syncytial virus and
neutrophil activation. Clin Exp Immunol. 2005;140(3):470–477.
35. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human
respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol.
2011;301(2):L148–L156.
36. Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccineenhanced disease. J Immunol. 2008;180(4):2376–2384.
37. Castilow EM, Legge KL, Varga SM. Cutting edge: eosinophils do not
contribute to respiratory syncytial virus vaccine-enhanced disease.
J Immunol. 2008;181(10):6692–6696.
38. Prestwood TR, Morar MM, Zellweger RM, et al. Gamma interferon
(IFN-γ) receptor restricts systemic dengue virus replication and prevents
paralysis in IFN-α/β receptor-deficient mice. J Virol. 2012;86(23):
12561–12570.

International Journal of Nanomedicine 2015:10

Dovepress

The roles of alveolar macrophages in RSV disease

Supplementary material
$

1DwYH

1DwYH

±



569LQIHFWLRQ








),569

)*9/3







&'F




3%6

















&/





                       

)

%



RI$0V





3%6
&/





569LQIHFWLRQ

1DwYH
±

1DwYH


),569


)*9/3


Figure S1 Clodronate treatment partially depletes AMs in the airways.
Notes: (A) Flow cytometry profiles gating AM phenotypic cells. (B) Percentages of AMs in the bronchoalveolar lavage fluids. CL was intranasally given to mice 4 hours prior
to RSV infection, and a control group was intranasally administered PBS. AMs were analyzed by flow cytometry 5 days later. The surface markers such as CD11c, CD11b, and
F4/80 antibodies were used to characterize AMs in the airways of individual mice (n=5). Statistical significance was determined using an unpaired two-tailed Student’s t-test.
Error bars indicate means ± standard error of the mean of concentration from individual animals (n=5). *P,0.05; ***P,0.001.
Abbreviations: AM, alveolar macrophage; CL, clodronate liposome; FG VLP, a combination of F and G virus-like nanoparticles; FI-RSV, formalin-inactivated RSV; PBS,
phosphate-buffered saline; RSV, respiratory syncytial virus.
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